December 1 2020 | Targeted Therapies in Oncology

December 1 2020

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine

December 09, 2020

Clinical Articles

Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer, redirecting attention toward advances in biomarker testing methodologies.

Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022

December 01, 2020

Clinical Articles

The MET inhibitor TPX-0022 was safe and well tolerated in a phase 1 dose-escalation study, SHIELD-1, involving patients with advanced solid tumors harboring MET alterations, according to results presented during the 32nd Molecular Targets and Cancer Therapeutics Symposium.